Eloralintide

01 · What is it?

The identity comes first.

Eloralintide is an engineered amylin-pathway compound studied for appetite and body-weight outcomes. It is distinct from cagrilintide and from CagriSema. Its selectivity is a molecular property, not proof of superior outcomes.

Scientific classification: Investigational peptide; selective long-acting amylin receptor agonist

For example. It is designed to deliver a persistent meal-related message with a more selective receptor profile.

02 · How does it work?

The signal, explained.

It is designed to activate the receiving system for amylin, a meal-related hormone. Researchers are testing whether its selective, longer-lasting signal changes clinical outcomes.

The key research focus is Amylin receptor complexes. A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

Amylin-sensitive neural circuits can influence satiety and food intake. Changes in receptor signaling must be connected to measured clinical outcomes and adverse events, rather than assuming appetite effects establish long-term benefit.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Scientists are studying body-weight outcomes and associated conditions, including obstructive sleep apnea and effects alongside incretin medicines.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Brain

Relevant to neural signaling, appetite, behavior or stress circuitry described above.

Digestive tract

Relevant to secretion, motility, epithelial transport or gut–brain signaling.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

Amylin receptor complexes

Secondary interactions

No additional primary target established for the research claim discussed.

Where it is found

Amylin-sensitive hindbrain and connected appetite circuits.

Activation, inhibition or interaction

Agonism involves calcitonin-receptor/RAMP complexes. Selective amylin receptor activity is intended to favor amylin signaling relative to calcitonin-receptor activity; the precise balance is assay-dependent.

Important downstream pathways

Amylin-sensitive neural circuits can influence satiety and food intake. Changes in receptor signaling must be connected to measured clinical outcomes and adverse events, rather than assuming appetite effects establish long-term benefit.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

Eli Lilly and Company

Development name: LY3841136

Program: ENLIGHTEN

Development phase: Phase 3

Example trial record: NCT07321886

Registry status when checked: Enrolling on Lilly Trials at the September 9, 2026 review.

Regulatory context: Investigational in the sponsor sources reviewed. Clinical development is not a product authorization.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

Investigational in the sponsor sources reviewed. Clinical development is not a product authorization.

Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.

The main evidence category here is human clinical research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.